» Articles » PMID: 15972690

Mannose-binding Lectin is a Regulator of Inflammation That Accompanies Myocardial Ischemia and Reperfusion Injury

Overview
Journal J Immunol
Date 2005 Jun 24
PMID 15972690
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

The mannose-binding lectin (MBL), a circulating pattern recognition molecule, recognizes a wide range of infectious agents with resultant initiation of the complement cascade in an Ab-independent manner. MBL recognizes infectious non-self and altered self in the guise of apoptotic and necrotic cells. In this study, we demonstrate that mice lacking MBL, and hence are devoid of MBL-dependent lectin pathway activation but have fully active alternative and classical complement pathways, are protected from cardiac reperfusion injury with resultant preservation of cardiac function. Significantly, mice that lack a major component of the classical complement pathway initiation complex (C1q) but have an intact MBL complement pathway, are not protected from injury. These results suggest that the MBL-dependent pathway of complement activation is a key regulator of myocardial reperfusion ischemic injury. MBL is an example of a pattern recognition molecule that plays a dual role in modifying inflammatory responses to sterile and infectious injury.

Citing Articles

Detrimental interactions of hypoxia and complement MASP-1 in endothelial cells as a model for atherosclerosis-related diseases.

Demeter F, Nemeth Z, Kajdacsi E, Bihari G, Dobo J, Gal P Sci Rep. 2024; 14(1):14882.

PMID: 38937560 PMC: 11211410. DOI: 10.1038/s41598-024-64479-6.


Bibliometric and visual analysis of intestinal ischemia reperfusion from 2004 to 2022.

Wan Y, Dong P, Zhu X, Lei Y, Shen J, Liu W Front Med (Lausanne). 2022; 9:963104.

PMID: 36052333 PMC: 9426633. DOI: 10.3389/fmed.2022.963104.


Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression.

Urwyler P, Moser S, Trendelenburg M, Sendi P, Osthoff M Mol Immunol. 2022; 150:99-113.

PMID: 36030710 PMC: 9393183. DOI: 10.1016/j.molimm.2022.08.008.


C1q as a target molecule to treat human disease: What do mouse studies teach us?.

Schulz K, Trendelenburg M Front Immunol. 2022; 13:958273.

PMID: 35990646 PMC: 9385197. DOI: 10.3389/fimmu.2022.958273.


Directed Evolution-Driven Increase of Structural Plasticity Is a Prerequisite for Binding the Complement Lectin Pathway Blocking MASP-Inhibitor Peptides.

Durvanger Z, Boros E, Nagy Z, Hegedus R, Megyeri M, Dobo J ACS Chem Biol. 2022; 17(4):969-986.

PMID: 35378038 PMC: 9016712. DOI: 10.1021/acschembio.2c00114.